» Articles » PMID: 27595987

Bibliometric Study of Research and Development for Neglected Diseases in the BRICS

Overview
Publisher Biomed Central
Date 2016 Sep 7
PMID 27595987
Citations 20
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Large numbers of people are suffering from a group of diseases that mainly affect developing countries, as there are no available or affordable products for prevention or treatment. Research and development (R&D) for these diseases is still a low priority on the health agenda. Brazil, Russia, India, China and South Africa (BRICS) are quickly growing economies and having more and more positive impact on global health. Additionally, their R&D capacity is believed to be enhanced through decades of investment in education and life science research. The BRICS, as a group of emerging and developing countries, are expected to make greater contributions to solving the problem that mainly affects the entire developing countries community. However, there has been little research to provide a macroscopic overview of BRICS' effort in R&D for neglected diseases. The aim of this study is to investigate scientific production in BRICS countries in this area and their main research hotspots.

Methods: Global relevant literature was searched without time limits through PubMed and high yield countries were identified using GoPubMed. Literature up to the end of 2013 from the BRICS was obtained and high frequency words were extracted and clustered using Bibliography Item Co-occurrence Mining System 2.0 (BICOMS) and Graphical Clustering Toolkit 1.0 (gCLUTO).

Results: In total, 32, 47, 51, 31 and 44 high frequency words from Brazil, Russia, India, China and South Africa respectively were extracted for clustering analysis. The clustering indicated that eight diseases were research hotspots in BRICS countries. India had the most extensive hotspots and Brazil came in second. The other three countries shared common research foci: helminthiasis, Human Immunodeficiency Virus infection and Acquired Immune Deficiency Syndrome (HIV/AIDS) and tuberculosis.

Conclusions: Developed countries still make the majority of contributions to R&D on neglected diseases, but BRICS countries are playing a growing role. Instead of the "big three diseases" (HIV/AIDS, malaria and tuberculosis) recognized by WHO, the BRICS focus more on major causes of disease burden in their own countries. Disease burden and domestic policy, especially patent law, exert primary influence on the research focus.

Citing Articles

Research on neglected tropical diseases in Haiti: a scientometrics analysis, 1923-2022.

Glesil M, Maciel A, Silva T, Ferreira A, Rocha A, Garcia G Cad Saude Publica. 2025; 41(1):e00020824.

PMID: 40008704 PMC: 11863633. DOI: 10.1590/0102-311XEN020824.


Clinical trial trends over the last 5 years among the BRICS (Brazil, Russia, India, China, and South Africa) nations.

Manoharan K, Jinson J, Ramesh K, George M Perspect Clin Res. 2024; 15(3):128-133.

PMID: 39140013 PMC: 11318790. DOI: 10.4103/picr.picr_179_23.


Mapping Knowledge Landscapes and Emerging Trends in AI for Dementia Biomarkers: Bibliometric and Visualization Analysis.

Qi W, Zhu X, He D, Wang B, Cao S, Dong C J Med Internet Res. 2024; 26:e57830.

PMID: 39116438 PMC: 11342017. DOI: 10.2196/57830.


Technical-scientific production and knowledge networks about medicinal plants and herbal medicines in the Amazon.

Lepsch-Cunha N, Muraro V, Nascimento H, Mazoni A, Nunez C, Bonacelli M Front Res Metr Anal. 2024; 9:1396472.

PMID: 38933653 PMC: 11199724. DOI: 10.3389/frma.2024.1396472.


Healthcare Policies to Eliminate Neglected Tropical Diseases (NTDs) in India: A Roadmap.

Chandra A, Sreeganga S, Rath N, Ramaprasad A Int J Environ Res Public Health. 2023; 20(19).

PMID: 37835112 PMC: 10572727. DOI: 10.3390/ijerph20196842.


References
1.
ANEJA K . Immunoprophylaxis in tuberculosis. J Commun Dis. 1984; 16(1):49-53. View

2.
Apt A, Avdienko V, Nikonenko B, Kramnik I, Moroz A, Skamene E . Distinct H-2 complex control of mortality, and immune responses to tuberculosis infection in virgin and BCG-vaccinated mice. Clin Exp Immunol. 1993; 94(2):322-9. PMC: 1534249. DOI: 10.1111/j.1365-2249.1993.tb03451.x. View

3.
Hendriks J, Coutinho S, Cysne L, Dorea R . Generation of Leishmania-specific short-term T-cell lines derived from peripheral blood of cured American cutaneous leishmaniasis patients. Ann Inst Pasteur Immunol. 1987; 138(4):561-9. DOI: 10.1016/s0769-2625(87)80126-5. View

4.
Maharaj B, Leary W, Pudifin D . A prospective study of hepatic tuberculosis in 41 black patients. Q J Med. 1987; 63(242):517-22. View

5.
Trouiller P, Olliaro P, Torreele E, Orbinski J, Laing R, Ford N . Drug development for neglected diseases: a deficient market and a public-health policy failure. Lancet. 2002; 359(9324):2188-94. DOI: 10.1016/S0140-6736(02)09096-7. View